10-Q: Geron Reports Q1 2025 Results: RYTELO Sales Flat, Company Faces Securities Lawsuits

Geron Corporation's Q1 2025 results reveal flat RYTELO sales growth and ongoing legal challenges, despite FDA and EC approvals.

Summary

• Geron Corporation reported a net loss of $19.8 million, or $0.03 per share, for the quarter ended March 31, 2025, compared to a net loss of $55.4 million, or $0.09 per share, for the same period in 2024.
• Net product revenue from RYTELO sales was $39.4 million for the quarter, with total revenues reaching $39.6 million.
• The company's operating expenses totaled $56.3 million, with research and development expenses at $15.1 million and selling, general, and administrative expenses at $40.0 million.
• As of March 31, 2025, Geron had $457.5 million in cash, cash equivalents, restricted cash, and marketable securities.
• Geron expects operating expenses for 2025 to range from $270 million to $285 million.
• The company is facing two securities class action lawsuits and three derivative complaints related to allegedly misleading statements about RYTELO's commercial potential.
• Geron anticipates an interim analysis for overall survival in its IMpactMF clinical trial in the second half of 2026 and a final analysis in the second half of 2028.
• The company received marketing authorization for RYTELO in the EU in March 2025 and plans for commercialization in select EU markets in 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is generating revenue and has a substantial cash position, it faces challenges with RYTELO sales growth, ongoing litigation, and the inherent risks of drug development and commercialization.

Positives

• Net loss decreased significantly compared to the same period last year.
• The company has a substantial amount of cash and marketable securities on hand.
• Geron received marketing authorization for RYTELO in the EU.
• Interest income increased due to a larger marketable securities portfolio.

Negatives

• RYTELO sales growth has flattened, raising concerns about its commercial potential.
• The company is facing multiple securities lawsuits, which could be costly and time-consuming.
• Interest expense increased due to debt and royalty financing agreements.
• The company has a history of net losses and may not achieve consistent future profitability for some time, if ever.

Risks

• The commercial potential of RYTELO remains unproven.
• The company's ability to generate meaningful revenue and achieve profitability is dependent on successfully commercializing RYTELO.
• The company is subject to risks common to companies in its industry and at its stage of development.
• The company may be unable to obtain additional capital if and when needed.
• The company is subject to risks related to its indebtedness and liabilities.
• The company is subject to risks related to protecting its intellectual property.
• The company is subject to risks related to managing its growth and other business operations.
• The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• The company is subject to risks related to information technology systems, data security and data privacy.
• The company is subject to risks related to its common stock and financial reporting.

Future Outlook

Geron plans to continue commercializing RYTELO in the U.S. and preparing for commercialization in select EU markets in 2026, while also continuing the clinical development of imetelstat for other myeloid hematologic malignancies.

Management Comments

• Our priority is to drive new patient starts across the breadth of the eligible patient population in RYTELOs approved indication in the U.S.

Industry Context

The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or comparable companies.
• The document does not contain specific project comparisons.

Management Changes

Corporate Governance

Legal Proceedings

• Geron and certain of its current and former officers are named as defendants in two putative securities class action lawsuits and three derivative complaints alleging false and misleading statements concerning the commercial potential of RYTELO.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by changes in company strategy and potential restructuring.
• Patients may benefit from the continued development and commercialization of RYTELO, but also face risks associated with its use.
• Suppliers and creditors are subject to the company's financial performance and ability to meet its obligations.

Next Steps

• Continue commercialization of RYTELO in the U.S.
• Prepare for commercialization of RYTELO in select EU markets in 2026.
• Continue clinical development of imetelstat for other myeloid hematologic malignancies.
• Defend against securities class action and derivative lawsuits.

Key Dates

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, MDS, myelofibrosis, MF, clinical trial, commercialization, FDA, EC, revenue, net loss, Pharmakon Loan Agreement, Royalty Pharma Agreement